A Full-Spectrum Evaluation of Sigma-1 Receptor (S1R) Positron Emission Tomography (PET) Radioligands from Binding Affinity to Clinical Imaging
Molecules · 2025
DOI: 10.3390/molecules30214296 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2025. Verfasst von Francesco Mastropasqua und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Via E. Orabona, 4, 70125 Bari, Italy. Hauptthemen laut MEDLINE: Receptors, sigma, Positron-Emission Tomography, Radiopharmaceuticals. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: #NEXTGENERATIONEU, Ministry of University and Research, National Recovery and Resilience Plan.
Abstract (Originalsprache)
Several pieces of evidence have demonstrated the sigma-1 receptor (S1R) as a druggable protein with important therapeutic potentials, including neurodegeneration, cancer, and neuropathic pain. The density of S1R is altered in pathological processes so that its imaging is under study for diagnostic purposes. Thus, research has been focused on the development of S1R positron emission tomography (PET) radioligands, not only as diagnostic tools but also as powerful means to assist in the drug-development process. Herein, we comprehensively review the most important S1R PET radiotracers belonging to different classes that have been developed in the last two decades. Starting from the structural modifications impacting on the S1R affinity and selectivity, we report (i) the differences in metabolism and pharmacokinetics, (ii) the in vivo behavior in different animal models, (iii) the in vitro autoradiography outcomes, and (iv) the dosimetric profiles. The successful use of the best-performing S1R PET radiotracers in the characterization of novel S1R drugs is also reported together with the approaches to assess the potential for clinical translation. What emerges from this review is that, although the development of reliable PET agents appears to be extremely challenging, these radiotracers hold incredible potential and play a fundamental role in the exploitation of S1R in health and disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Via E. Orabona, 4, 70125 Bari, Italy.
- Department of Experimental Neurooncological Radiopharmacy, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Research Site Leipzig, Permoserstraße 15, 04318 Leipzig, Germany.
ORCID-Profile: Francesco Mastropasqua, Friedrich-Alexander Ludwig, Carmen Abate
Förderung
- #NEXTGENERATIONEU
- Ministry of University and Research
- National Recovery and Resilience Plan
- project MNESYS
- National Research Council
Zitieren
APA
Mastropasqua, F., Ludwig, F. A., & Abate, C. (2025). A Full-Spectrum Evaluation of Sigma-1 Receptor (S1R) Positron Emission Tomography (PET) Radioligands from Binding Affinity to Clinical Imaging. Molecules. https://doi.org/10.3390/molecules30214296
Vancouver
Mastropasqua F, Ludwig FA, Abate C. A Full-Spectrum Evaluation of Sigma-1 Receptor (S1R) Positron Emission Tomography (PET) Radioligands from Binding Affinity to Clinical Imaging. Molecules. 2025. doi:10.3390/molecules30214296
BibTeX
@article{Mastropasqua2025,
author = {Mastropasqua, Francesco and Ludwig, Friedrich-Alexander and Abate, Carmen},
title = {A Full-Spectrum Evaluation of Sigma-1 Receptor (S1R) Positron Emission Tomography (PET) Radioligands from Binding Affinity to Clinical Imaging},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30214296}
}
EUVIMED